Health
Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection
Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) has approved TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine designed to provide broad respiratory disease protection. The approval of TruCan Ultra CIV completes Elanco's Tru Portfolio of comfortable and convenient combination vaccines made with PureFil™ Technology, an exclusive process for creating highly purified vaccines designed to reduce adverse reactions and deliver better experi
About this update from Elanco Animal Health Incorporated
[{"type":"list","items":[{"val":[{"type":"text","content":"TruCan Ultra CIV is the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine offering broad protection against H3N2 and H3N8.","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"100% virus neutralization against 33 current field isolates.1","length":61,"tagName":"p"}]},{"val":[{"type":"text","content":"Unlike currently available products, only TruCan Ultra CIV demonstrates zero lung lesions in vaccinated dogs post H3N2 challenge.2,3,4","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"TruCan Ultra CIV completes Elanco's extensive line of Tru Portfolio vaccines.","length":81,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":414,"olType":false},{"type":"text","content":"GREENFIELD, Ind., July 9, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) has approved TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine designed to provide broad respiratory disease protection. The approval of TruCan Ultra CIV completes Elanco's Tru Portfolio of comfortable and convenient combination vaccines made with PureFil™ Technology, an exclusive process for creating highly purified vaccines designed to reduce adverse reactions and deliver better experiences.","length":562,"tagName":"p"},{"type":"text","content":"In Canine Influenza Virus (CIV) studies, TruCan Ultra CIV was shown to be highly effective in protecting dogs' lungs and improving clinical signs:","length":150,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Zero vaccinated dogs developed lung lesions post H3N2 challenge2","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"100% neutralization of 33 currently circulating CIV field isolates1","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Proven to reduce viral shedding2,5","length":34,"tagName":"p"}]},{"val":[{"type":"text","content":"Proven safe across multiple breed and ages in field safety study5","length":65,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":230,"olType":false},{"type":"text","content":""With the recent USDA approval for TruCan Ultra CIV, Elanco continues to lead the charge in innovative animal health solutions," said Bobby Modi, Executive Vice President, U.S. Pet Health and ...